Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31410710 | 0.82 | ESR2 (0.76) | ESR2PTPN5TRPA1ALDH1A1FFAR1 | |
| SCHEMBL1666926 | 0.80 | DRD1 (0.60) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL9846028 | 0.79 | ESR2 (0.56) | ESR2PTPN5TRPA1FFAR1AKR1B1 | |
| SCHEMBL1261594 | 0.79 | ALDH1A1 (0.43) | ESR2ALDH1A1CYP2A6GABRG2GABRB3 | |
| SCHEMBL7571095 | 0.79 | ALDH1A1 (0.46) | ESR2ALDH1A1CYP2A6GABRG2GABRB3 | |
| SCHEMBL7577589 | 0.78 | KDM4E (0.43) | ESR2ALDH1A1GABRG2GABRB3GABRA5 | |
| Benzaldehyde SCHEMBL23142677 | 0.78 | ALDH1A1 (0.64) | TRPA1ALDH1A1CYP2A6EGFRHPGD | |
| SCHEMBL2016996 | 0.78 | ESR2 (0.70) | ESR2PTPN5TRPA1ALDH1A1FFAR1 | |
| SCHEMBL29733602 | 0.78 | DRD1 (0.58) | DRD1DRD2DRD4DRD5DRD3 | |
| SCHEMBL29733609 | 0.78 | DRD1 (0.58) | DRD1DRD2DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072923-A1 | Process for producing 2'-(1h-tetrazol-5-yl)biphenyl-4-carbaldehyde | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-03-29 | — | — | US | claimed |
| EP-1666471-A1 | PROCESS FOR PRODUCING 2' -(1H-TETRAZOL-5-YL)-BIPHENYL-4-CARBALDEHYDE | Sumitomo Chemical Company, Limited (JP) | 2006-06-07 | — | — | EP | claimed |
| CN-113993851-B | Valsartan refining method | 浙江华海药业股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2023148748-A1 | AN IMPROVED SAFE PROCESS FOR THE PREPARATION OF SARTAN DRUGS OF FORMULA I | IOL CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
| CN-113727976-B | Refining method of valsartan compound | 浙江华海药业股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230119053-A1 | Process for Preparing Sartan Active Compounds Having a Tetrazole Ring | SANOFI (FR) | 2023-04-20 | — | — | US | disclosed |
| CN-115197096-A | Synthesis method of valsartan intermediate | 山东新时代药业有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-113993851-A | Valsartan refining method | 浙江华海药业股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113727976-A | Refining method of valsartan compound | 浙江华海药业股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2021022516-A1 | VALSARTAN REFINEMENT METHOD | 浙江华海药业股份有限公司 | 2021-02-11 | — | — | WO | disclosed |
| WO-2020252662-A1 | METHOD FOR REFINING VALSARTAN COMPOUND | 浙江华海药业股份有限公司 | 2020-12-24 | — | — | WO | disclosed |
| CN-1147515-A | Producing process for crystal of 2-oxyethyl-1-[2'-(1H-tetrazole-5-radical)diphenyl-4-(methyl)benzimidazole-7-hydroxy acid 1-(cyclohexyloxy) ethyl ester | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-04-16 | — | — | CN | disclosed |
| EP-0720982-A1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-10 | — | — | EP | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| US-5380719-A | Quinoxaline biphenyl angiotensin II inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0459136-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-12-04 | — | — | EP | disclosed |
| CN-1055927-A | Benzimidazole derivatives, their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1991-11-06 | — | — | CN | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
| EP-0424317-A2 | Pyrimidines | CIBA-GEIGY AG (CH) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119053-A1 | Process for Preparing Sartan Active Compounds Having a Tetrazole Ring | CYP3A7, UGT1A9, UGT1A7 | ESR2 4675/4885PTPN5 2883/4885DRD1 1245/4885 |
| US-20070072923-A1 | Process for producing 2'-(1h-tetrazol-5-yl)biphenyl-4-carbaldehyde | TH, CYP4B1, ABL1 | ESR2 4762/4885PTPN5 136/4885DRD1 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.